| Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of … T Knox, E Sahakian, D Banik, M Hadley, E Palmer, S Noonepalle, J Kim, ... Scientific reports 9 (1), 6136, 2019 | 146 | 2019 |
| Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation KV Woan, M Lienlaf, P Perez-Villaroel, C Lee, F Cheng, T Knox, ... Molecular oncology 9 (7), 1447-1457, 2015 | 146 | 2015 |
| Essential role of HDAC6 in the regulation of PD-L1 in melanoma M Lienlaf, P Perez-Villarroel, T Knox, M Pabon, E Sahakian, J Powers, ... Molecular oncology 10 (5), 735-750, 2016 | 144 | 2016 |
| Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function E Sahakian, JJ Powers, J Chen, SL Deng, F Cheng, A Distler, DM Woods, ... Molecular immunology 63 (2), 579-585, 2015 | 126 | 2015 |
| Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice CL Kriss, JA Pinilla-Ibarz, AW Mailloux, JJ Powers, CHA Tang, CW Kang, ... Blood, The Journal of the American Society of Hematology 120 (5), 1027-1038, 2012 | 80 | 2012 |
| TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures RA Chaurio, CM Anadon, TL Costich, KK Payne, S Biswas, CM Harro, ... Immunity 55 (1), 115-128. e9, 2022 | 79 | 2022 |
| Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells CM Anadon, X Yu, K Hänggi, S Biswas, RA Chaurio, A Martin, KK Payne, ... Cancer Cell 40 (5), 545-557. e13, 2022 | 70 | 2022 |
| T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model DM Woods, KV Woan, F Cheng, AL Sodré, D Wang, Y Wu, Z Wang, ... Blood, The Journal of the American Society of Hematology 130 (2), 146-155, 2017 | 69 | 2017 |
| WT 1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides J Brayer, JE Lancet, J Powers, A List, L Balducci, R Komrokji, ... American journal of hematology 90 (7), 602-607, 2015 | 69 | 2015 |
| The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells K Maharaj, JJ Powers, A Achille, M Mediavilla-Varela, W Gamal, ... Blood advances 4 (13), 3072-3084, 2020 | 63 | 2020 |
| Essential role for histone deacetylase 11 (HDAC11) in neutrophil biology E Sahakian, J Chen, JJ Powers, X Chen, K Maharaj, SL Deng, AN Achille, ... Journal of leukocyte biology 102 (2), 475-486, 2017 | 55 | 2017 |
| A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease K Sweet, L Hazlehurst, E Sahakian, J Powers, L Nodzon, F Kayali, ... Leukemia research 74, 89-96, 2018 | 52 | 2018 |
| Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen JA Dubovsky, DG McNeel, JJ Powers, J Gordon, EM Sotomayor, ... Clinical Cancer Research 15 (10), 3406-3415, 2009 | 52 | 2009 |
| HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms L Yue, V Sharma, NP Horvat, AA Akuffo, MS Beatty, C Murdun, C Colin, ... Blood, The Journal of the American Society of Hematology 135 (3), 191-207, 2020 | 48 | 2020 |
| A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors JJ Powers, JA Dubovsky, PK Epling-Burnette, L Moscinski, L Zhang, ... Leukemia & lymphoma 52 (4), 668-679, 2011 | 46 | 2011 |
| IgA-dominated humoral immune responses govern patients' outcome in endometrial cancer G Mandal, S Biswas, CM Anadon, X Yu, CD Gatenbee, S Prabhakaran, ... Cancer research 82 (5), 859-871, 2022 | 32 | 2022 |
| Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers JA Dubovsky, D Wang, JJ Powers, E Berchmans, MA Smith, KL Wright, ... Leukemia research 35 (3), 394-404, 2011 | 26 | 2011 |
| Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia JC Chavez, M Piris-Villaespesa, S Dalia, J Powers, E Turba, L Nodzon, ... Leukemia research 47, 78-83, 2016 | 23 | 2016 |
| Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia K Maharaj, JJ Powers, A Achille, S Deng, R Fonseca, M Pabon-Saldana, ... Blood advances 2 (21), 3012-3024, 2018 | 22 | 2018 |
| HDAC6 inhibition alleviates CLL-induced T-cell dysfunction and enhances immune checkpoint blockade efficacy in the Eμ-TCL1 model K Maharaj, JJ Powers, M Mediavilla-Varela, A Achille, W Gamal, S Quayle, ... Frontiers in Immunology 11, 590072, 2020 | 20 | 2020 |
Eva Sahakian, Ph.DSenior Research Scientist Moffitt cancer center; Assistant Professor USF Morsani School of Medicine在 moffitt.org 的电子邮件经过验证
